The collaboration combines Innovent's proven immuno-oncology ("IO") and antibody-drug conjugate ("ADC") R&D capability and Takeda's experience in global oncology drug development to accelerate Innovent's two late-stage investigational medicines worldwide, and Takeda receives an option for an early-stage program.

Innovent and Takeda will co-develop the IO backbone therapy IBI363 (PD-1/IL-2 α-bias ) globally and co-commercialize it in the U.S., where Takeda will lead the co-development and co-commercialization efforts under joint governance and aligned development plan; Takeda will receive exclusive commercialization rights outside Greater China and the U.S.

Innovent will grant Takeda exclusive rights for IBI343 (CLDN18.2 ADC) outside Greater China.

Innovent will grant Takeda an exclusi

See Full Page